Evidence map›Paper›PMID 30088231›Full record

ArticleJournal of applied genetics2018

hTERT promoter methylation status in peripheral blood leukocytes as a molecular marker of head and neck cancer progression.

Agnieszka Sobecka, Wiktoria Blaszczak, Wojciech Barczak, Pawel Golusinski, Blazej Rubis, Michal M Masternak, Wiktoria M Suchorska, Wojciech Golusinski

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Journal of applied genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Head and Neck Squamous Cell Carcinoma: Epigenetic Landscape.Diagnostics (Basel, Switzerland) · 2020
    Review
  3. Article
  4. Studies of hTERT DNA methylation assays on the human age prediction.International journal of legal medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Agnieszka Sobecka *Department of Head and Neck Surgery, The Greater Poland Cancer Centre, Poznan University of Medical Sciences, Garbary 15 Str, 61-866, Poznan, Poland.
Wiktoria Blaszczak *Radiobiology Laboratory, The Greater Poland Cancer Centre, Garbary 15 Str, 61-866, Poznan, Poland.
Wojciech BarczakDepartment of Head and Neck Surgery, The Greater Poland Cancer Centre, Poznan University of Medical Sciences, Garbary 15 Str, 61-866, Poznan, Poland. wbarczak@ump.edu.pl.ORCID http://orcid.org/0000-0002-9603-2028
Pawel GolusinskiDepartment of Head and Neck Surgery, The Greater Poland Cancer Centre, Poznan University of Medical Sciences, Garbary 15 Str, 61-866, Poznan, Poland.
Blazej RubisDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Przybyszewskiego 49 Str, 60-355, Poznan, Poland.
Michal M MasternakDepartment of Head and Neck Surgery, The Greater Poland Cancer Centre, Poznan University of Medical Sciences, Garbary 15 Str, 61-866, Poznan, Poland.
Wiktoria M SuchorskaRadiobiology Laboratory, The Greater Poland Cancer Centre, Garbary 15 Str, 61-866, Poznan, Poland.
Wojciech GolusinskiDepartment of Head and Neck Surgery, The Greater Poland Cancer Centre, Poznan University of Medical Sciences, Garbary 15 Str, 61-866, Poznan, Poland.
Poznan University of Medical Sciences · PLGreater Poland Cancer Center · PLUniversity of Central Florida · US

Funding

Narodowe Centrum Nauki 2015/17/N/NZ5/00686Poznan University of Medical Sciences 502-14-02211330-41221
6 · The paper itself

Abstract

Cancer cells, including head and neck cancer cell carcinoma (HNSCC), are characterized by an increased telomerase activity. This enzymatic complex is active in approximately 80-90% of all malignancies, and is regulated by various factors, including methylation status of hTERT gene promoter. hTERT methylation pattern has been thoroughly studied so far. It was proved that hTERT is aberrantly methylated in tumor tissue versus healthy counterparts. However, such effect has not yet been investigated in PBLs (peripheral blood leukocytes) of cancer patients. The aim of this study was to analyze the hTERT gene promoter methylation status in blood leukocytes. DNA was extracted from PBL of 92 patients with histologically diagnosed HNSCC and 53 healthy controls. Methylation status of whole hTERT promoter fragment with independent analysis of each 19 CpG sites was performed using bisulfide conversion technique followed by sequencing of PCR products. Not significant (p = 0.0532) differences in the general frequency of hTERT CpG sites methylation were detected between patients and healthy controls. However, it was discovered that some of analyzed positions (CpG islands: 1 [p = 0.0235], 5 [p = 0.0462], 8 [p = 0.0343]) are significantly more often methylated in HNSCC patients than in controls. The opposite finding was observed in case of CpG position 2 (p = 0.0210). Furthermore, closer analysis of single CpG positions revealed differences in methylation status dependent on anatomical site and TNM classification. To conclude, hTERT promoter methylation status (general or single CpG sites) would be considered as a molecular markers of HNSCC diagnostics.

Indexed as

DNA MethylationPromoter Regions, GeneticAdultAgedAged, 80 and overCase-Control StudiesCpG IslandsDisease ProgressionFemaleHead and Neck NeoplasmsHumansLeukocytesMaleMiddle AgedSequence Analysis, DNATelomeraseTelomeraseTERT protein, humanBiomarkerHead and neck cancerhTERTMethylationTelomerase

Identifiers

PMID30088231
OpenAlexW2887181593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.